Oral Drug Delivery System: A Review

Ms. Hina Umar Momin*, Prof. Santosh Waghmare, Dr. H. V. Kamble

Department of Pharmaceutical Chemistry[1], Department of Pharmaceutical Chemistry[2], Department of Pharmacology[3]
[1, 2, 3] Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharata.

ABSTRACT: Oral administration of medicine in one of the preferred route and extensively used expression for new living and new medicines. The new generation of oral medicine delivery system technologies brings precious benefits to cases. Oral route is the most accessible and generally route of medicine delivery. It might be due to its ease of administration and utmost impotently patient compliance. Oral controlled release phrasings are designed to deliver a medicine at a pre determined rate by achieving a constant medicine position for a specified period of time with lower side goods. Controlled release medicine delivery have come a significant precedence worldwide, it may be possible to achieve rapid-fire immersion of medicine and increased memoir vacuity, reduced toxin and bettered patient compliance. The oral route is by far the most common route of medicine administration in the gastrointestinal tract and can be used for both systemic medicine delivery and for treating original gastrointestinal conditions. It's the most favored route by cases, due to its advantages, similar as ease of use,non-invasiveness, and convenience for tone-administration. Phrasings can also be designed to enhance medicine delivery to specific regions in the upper or lower gastrointestinal tract. Despite the clear advantages offered by the oral route, medicine delivery can be grueling as the mortal gastrointestinal tract is complex and displays a number of physiological walls that affect medicine delivery. A recent report by new England health care institute stated that the cost of non- compliance alone in us was around$ 290 billion, 13 of total periodic health care expenditure. Further over oral specifics bettered patient compliance and results in affective treatment which redounded in invention in oral medicine delivery system.
Key Words: Drug, Oral Drug Delivery System, formulation, gastrointestinal disease.

I.   INTRODUCTION

The oral route is by far the most common route for medicine administration in the gastrointestinal tract (GI tract) and can be used for both systemic medicine delivery and for treating original gastrointestinal conditions. It's the most favored route by cases, due to its advantages, similar as ease of use, non-invasiveness, and convenience for tone- administration. Phrasings can also be designed to enhance medicine delivery to specific regions in the upper or lower GI tract. The upper GI tract consists of the mouth, pharynx, esophagus, stomach, and the first part of the small intestine (duodenum), whereas the lower GI tract includes the other corridor of the small intestine (jejunum and ileum) and the large intestine (cecum, colon, and rectum) (1,2). Medicines administered via the oral route, still, generally have slower immersion, which isn't preferred during an exigency (3, 4). They might also be unwelcome in taste, beget gastric vexation, and/ or suffer first-pass medicine elimination processes in both the intestine and liver (5,6). In addition, the physiological terrain in the GI tract can also affect the stability and solubility of medicines (7,8).

There are generally three main pretensions in expression design for the oral route of gastrointestinal medicine delivery (9,10) (i) original medicine delivery to treat gastrointestinal complaint, whereby the medicine generally needs to be taken up into gastrointestinal mucosa but won't be systemically absorbed or will be inadequately absorbed; (ii) systemic medicine delivery, where medicine immersion needs to be suitable to cut the mucosal wall into the systemic rotation; and (iii) increase dissolution rate of inadequately answerable medicines, which generally doesn't bear the expression to cross the mucosa or cells. Medicine immersion in the GI tract is governed by numerous factors similar as face area for immersion, blood inflow to the point

of immersion, the physical state of the medicine (similar as a result, suspense or solid lozenge form), its water solubility, and the attention of the medicine at the point of immersion (11, 12). For immersion to do, medicines must be suitable to access the epithelium, which is the inmost subcaste that forms a nonstop filling of the entire GI tract. This epithelial cell hedge widely regulates transport from the lumen to the underpinning towel cube. Medicine motes can be transported passively via paracellular prolixity (between cells) and transcellular prolixity (through the cell) or laboriously via receptor- intermediated endocytosis and carrier- intermediated transport. Of these pathways, the transcellular route is the main medium of medicine immersion in the GI tract and is generally commensurable to the lipid solubility of the medicine (13,14). Thus, immersion is favored when the medicine patch is in thenon-ionized form, which is much further lipophilic than the ionized form. Oral medicine delivery is a significant area of expression exploration due to the forenamed advantages for cases. Significant pharmaceutical advances have been made to ameliorate the indigenous targeting of medicines in the GI tract, still veritably many of them have restated to the clinical phase. This review will bandy the physiological, pathophysiological, and pharmaceutical considerations impacting medicine delivery for the oral route of administration, as well as the conventional and new medicine delivery approaches. The translational challenges and development aspects of new phrasings will also be addressed.

Biomedical exploration has advanced our understanding of conditions — their causes and remedies. Specifically, the reme-dies that include approaches to help, manage, or treat a particular complaint using a medicine (e.g., chemical and birth motes) or a medicine-suchlike (e.g., supplements) emulsion. The pace at which new conditions, newer pathways of formerly known conditions, and adding understanding of the medicine-resistant mechanisms are being uncovered is accelerating. This pace isn't met by the discovery of new and effective drugs (15, 16). To meet this gap, adding attention is paid toward medicine displacing, where an being medicine discovered for a specific target is repurposed for other targets (). The primary advantage of medicine repurposing is that scientists formerly understand the pharmacology and safety biographies that can greatly reduce the threat of waste in medicine development in clinical phases. The medicine repurposing backed by artificial intelligence, systems pharmacology, and other computational approaches validate the medicine targets (19, 20). The effective delivery strategies would ameliorate threat- benefit biographies and switch routes of administration (21, 22). Each mode of delivery similar as oral, nasal, injection, sublingual, rectal, vaginal, optical, optical, or nasal has its separate advantages and disadvantages (23, 24). Nonetheless, oral medicine delivery (capsules, maquillages, dormancies, and results) is the singular, superior system of administration due to its convenience and safety compared with other styles (25, 26). Enterocytes, tableware cells, and Peyer's patches with M cells make the intestinal epithelium an optimal platform for medicine immersion. Especially regarding conditions that bear frequent administra-tion for a long duration, patient comfort proves oral medicine delivery's eminence. The advantages of oral medicine administra-tion over other styles include ease of use, being effortless, lower cost of care, lower patient supervision, and advanced patient compliance.

Still, the oral route of medicine administration has some disadvantages when it comes to the medicine motes flaunting low solubility, lower permeability, and declination rates. Also, the uptake of certain biomolecules/ medicines in oral route is largely affected by physiologic walls similar as pH change in gastrointestinal tract (GIT) acidic pH in the stomach followed by introductory pH in the intestine and enzymatic declination (27, 28). Nearly 60 of medicines de- grade in the harsh gastric surroundings of the stomach. Numerous have theorized making mariners out of the medicines, thereby in- furrowing its solubility and bioavailability (29, 30). Unfortunately, in practice, pairing the parent medicine with an applicable counter ion, for sufficient ionic commerce, has proven delicate. Only under ideal thermodynamic conditions will the swab medicine precipitate. Likewise, counter ions increase the weight of the medicine but are therapeutically inactive, therefore dragooning increased and frequent lozenge, which has necessary side goods on the body. Also, these fight ions increase the hygroscopic nature of the medicine by forming hydrates, and in consequence, reduce the medicine's shelf life. Some counter ions also parade a sharp nature, like hydrochlorides, and hence reduce the solubility of the medicine in the stomach as explained by the counter ion effect (31, 32). These issues motivated experimenters to attempt innovative forms of con-ventional carriers like capsules, tablets, microcapsules, ornon-

conventional approaches similar as intestinal patches and nanoparticles. The successes withnon-conventional delivery systems corroborate our belief that oral delivery deserves further attention for its possible advantages. The recent developments in the area of oral controlled release delivery systems similar as pate tablets, binary medicine tablets, intestinal patches, polymer nanosystems, or bioins-pired delivery systems similar as exosomes, have revolutionized the field. This review is an attempt to epitomize the oral medicine delivery ways available and under development, with current status for use and unborn prospects.

Modified oral release medicine delivery system has been developed to extend the medicine release for several hours (by combining medicine with release-retardant material to form matrix core or by applying release modifying film fleece over the core medicine material). The MR system offers reduction in dosing frequence. Low prevalence of side goods and better remedial effect and improvement of bioavailability.

Physiological and physicochemical factors affecting Modified release Technology

The mortal GI tract is a complex organ. The physiological factors that control immersion of medicine include Gsatric and intestinal transent time. Fluid and food input, gastric and intestinal stashing, absorptive medium. pH metabolism. The physicochemical factors include solubility, stability, ionisation and lipophilicity. By controlling both physiological and physicochemical factors we can successfully design modified release medicine delivery system. The topmost challenge in the design modified release phrasings is changing the nature of immediate release of the small intestine and extended release medication throughout the small intestine and eventually colon (33, 34). Conveyance time in GI tract is also one of the major factors that affect the effectiveness of MR lozenge form as it directly influences the point of medicine release. Different the point of medicine release bear change in pH and water content on posterior medicine immersion (35,36).

Table no 1: Approximate Fluid Flux, pH, and Residence Time within the gastrointestinal tract

Section	Fluid	input/day (ml)	Output/day(ml)	pH	Residence time (h)
Mouth	Water Saliva	1200_1500			
Stomach	Gastric Fluid	2000		1-3.5	0.5-12
	Pancreatic juice	1500			
Duodenum				4-6.5	
	Bile	500			3-4
Jejunum				5-7	
	Intestinal secretions	1500	8500		
Ileum				6-8	
Colon	Fluid transfer	500	350	6-8	10d

The rate of gastric empting depends on state and size of lozenge form and the presence and composition of food, intestinal conveyance timeetc. hence there must be interplay between GI physiology and expression design for the success of modified release medicine product (37, 38).

Factor impacting performance of modified medicines expression
Food

The influence of food on the bioavailability of medicine must be delved for safety and efficacity. If any food goods are plant also a justified cure with respect to the product input in relation to refections is given4.

Gastro-Intestinal function
By the modified release expression is co-conducted with medicine affecting GI tract physiology also disquisition related to MR lozenge form must be done.

Quotidian Measures
Tube attention profile measured for 24 hrs at steady state of any difference occurs in view of Day/ night.

Point of operation
The immersion of medicine at different point must be delved of the operation point in not limited to one body area.

Cure jilting
The chances of unanticipated release of medicine

performing in inferior advanced exposure do when the MR expression contains advanced compared to immediate release product.

Tablets

Oral tablets are the most common, accessible, and easy system for medicine administration. Tablets are conventionally made by compressing medicine greasepaint with applicable excipi-ents that affect in rapid-fire release of the medicine in the body when taken. The debit of conventional tablets is that rapid-fire medicine release makes it delicate to maintainmulti-component medicine release. Numerous controlled medicine release- grounded technologies similar as matrix tablets, multilayer tablets, Dome-matrix grounded tablets, core-in-mug bias, three-dimensional (3D) tablets,etc., have been developed or are under development (41-43) to deal with the downsides faced in conventional tablets. Matrix- tablets have been developed to attack the controlled medicine delivery issues faced in conventional tablets (Fig. 1) (44-48). The advantages of matrix tablets include lower frequent dosing, cost effectiveness, side- effect reduction from cure jilting, etc. Matrix- grounded systems are divided into three types 1) bibulous pump systems; 2) force matrix systems; and 3) megalith matrix systems. The bibulous pressure plays an important part in bibulous pump systems in which a semipermeable membrane with an perforation controls the medicine release. In the case of force matrix systems, a membrane controls the prolixity of the medicine from the system, whereas, in megalith matrix systems, the medicine has been dispersed or reprised in a hydrophobic or hydrophilic system, which controls the medicine release.

Multilayered tablets, including bilayered, triadic concentrated, and quadruple concentrated,etc., can be designed to release multiple medicines at different rates and are superior to conventional tablets. In general, the multilayered tablets correspond of a medicine core that's girdled by a hydrophobic or hydro-philic polymer subcaste that controls the medicine release in the GIT. Numerous multilayered tablets have been developed, similar as Geomatrix multilayer tablet technology, Smartrix technology, Sodas multilayer tablet technology, VersaTab bilayered tablet technology, Geolock technology, Procise technology, Chronotropic, Canons,etc. (Table 2) (49-53). The pate matrix- grounded medicine-releasing bias correspond of a pate- shaped swellable matrix module with a convex front and hollow base as shown inFig. 2. These tablets have two configurations 1) void configuration and 2) piled config-uration. The medicine release patterns in case of pate-matrix tablets are controlled by the configuration of modules (). A advanced medicine release rate has been observed for the convex front in comparison with the hollow base. The pate-matrix tablets showed a advanced original medicine release rate compared with conventional tablets. Dragged delivery of norfloxacin as pate-matrix tablet ways has also been established in the once 56, 57), but due to the complexity of these module systems, these tablets aren't as popular as other controlled release systems yet. To the stylish of our knowledge, this technology is still at exploratory position. Still, similar technologies will have significant impact in treating acute/ habitual conditions involving multiple progres- sion pathways, where multiple medicines are demanded to block the complaint progress.

Polymer- grounded 3D published tablets have been fabricated to maintain controlled medicine release over a particular time period to retain the remedial position of the medicine input. The 3D published tablets can be produced by colorful styles similar as 3D inkjet printing (58, 59), an extrusion- grounded (60-64), or a fused deposit modeling (65-69). These tablets demonstrate high medicine lading and immediate medicine release while maintaining the active physical form of the medicine. The size, as well as the shape of the simulated tablets can be modified according to the substantiated use. These tablets can also be fabricated with a large number of shorter perforated channels with particular range and length to control the medicine release as the show inFig. 3.

Roberts and associates (74) fabricated a 3D polypill with multiple active medicine motes con-fined in well- defined promised chambers for con- combed medicine release for the treatment of hypertension in type I diabetic cases. Captopril, glipizide, and nifedipine were used to make a 3D polypill (Fig. 4). The captopril medicine release was maintained through an zilches-motic pump- grounded medium, whereas glipizide and ni-fedipine showed the Korsmeyer-Peppas release kinetics. The study showed that a 3D polypill was suitable to deliver all three medicines without any sensible commerce between them.

Fig. 1. Image showing drug release from the matrix tablets. Adapted and modified from[70].

TABLE 2
Summary of various advanced tablet technologies Adapted and Modified from[71-73].

Drug	Technology	Design	Factors Affecting Drug Release	Advantages	Reference
Venlafaxine hydrochloride	Procise	Drug core with a hole	Core geometry	Zero-order kinetics or drug release according to core geometry	Malewar et al. (2015)
Diltiazem	Geomatrix	Multilayer tablet	Polymer type, thickness of layer	Zero-order kinetics and controlled drug release	Wilding et al. (1995)
Indomethacin	Smartrix	Multilayer tablet with specific shape of core layer	Polymer type, shape of core layer	Zero-order kinetics or drug release according to shape of core layer	Omer et al. (2017)
Methylphenidate	Sodas (spheroidal oral drug absorption system)	Multilayer tablet	Layer thickness, shape of core layer	Pulsatile drug release	Biederman et al. (2003)
Norfloxacin	Dome matrix	Dome-shaped swellable matrix module	Polymer used, module arrangement	Drug release based on module arrangement	Oliveira et al. (2011)
Fenofibrate captopril, glipizide, and nifedipine	3D printed tablets	Fabrication through 3D inkjet printing or an extrusion-based or fused deposition modelling	Polymer used, drug used	Immediate or controlled release	Khaled et al. (2015); Kyobula et al. (2017)
Insulin, camostat	Chronotopic	Multilayer tablet	Polymer layers	"Two pulse" release and	Del Curto et al.

mesilate				controlled release	(2011)
Heparin	GIPET	Permeation enhancement technology	Polymer layer, medium fatty chains	Immediate or modified acid release	Leonard et al. (2006)
Calcitonin	Peptellig ence	Permeation enhancement technology	Polymer layers, a permeation enhancer and the main excipient citric acid	Immediate or modified release	Binkley et al. (2012)
Insulin, lactulose	CODES	Multilayer tablet	Polymer layers, based release	Immediate or pH-controlled release	Katsuma et al. (2004)

The aim of these technologies is to enhance the bioavail- ability of drug molecules. Many of the above mentioned technologies are under clinical trials, but there are still numerous challenges that need to be tackled to use these technologies in real time. A summary of various controlled release tablet technologies has been done below (Table 2).


Fig. 2. (A) Dome matrix tablet module with void configuration (B) and piled configuration (C). Adapted and modified from [76-78].


Fig. 3. Image showing perforated channels in 3D channeled tablet: (A) parallel and (B) at right angle to long axis. Adapted and modified from[76-78].

Multilayered Tablet:

The multilayered tablet approached is a accessible system in which the lading cure is squeezed two external matrix layers. The central subcaste releases the cure for immediate onset of action whereas the matrix subcaste for sustained release of medicine. This helps in maintaining the blood position. The multilayered tablets are prepared by direct contraction or wet granulation or tablet contraction. The polymer used is ethyl cellulose, Eudragit RS 100. The challenges faced during multilayered tabletting include cross impurity from one subcaste to other (79-81).

Illustration if the first subcaste is red and alternate is white any granulation bypass the first confluent and pollute leading to pink color.

Uses :

Two inharmonious actives or excipients are compressed into one to make a high weight tablet.
Control release and time release.

Imprinting (molecular):

Molecular imprinting provides lithography system and technology for operation in the manufacturing, areas similar as Nano- bias, advanced packaging, microstructure, memoir bias, semiconducting bias and optic factors (82-85).

The conception behind the technology is to fester a material around individual motes. When the molecular templates are removed, one is left template patch. This shows that molecular imprinting is applicable to that material that can widely bind to motes of interest.

## Working of molecular imprinting:

Three introductory constituents are needed videlicet templates patch, functional monomers and a cross linker. The templates motes may range from small organic motes to large biopolymers. The templates must be purified, catalyzed or detected with the final product. These bear analogous to high energy interceders in the chemical response. Functional monomer should have two functional group each one end they should interact with templates with weak commerce (non-covalent) with the cross linkier. Cross linkers is a patch that can be polymerized around the templates, binding covalently to the functional monomers and holding them in place after the templates in removed pervious cross linkers or those which can be broken into small pieces are used generally (86-90).

Accudep technology:

Accudep technology has been developed for products for immediate release lozenge form, super general products ment, new controlled release phrasings. The main thing of this technology is to identify largely flexible delivery design that will accommodate numerous medicines of different physicochemical characteristics and cure grease engineering of immediate as well as control release of active pharmaceutical greasepaint. This process excludes processer similar as mixing blending, granulation, drying, contractionetc. and uses active component in pure form and achieves control release by the use of polymeric flicks (91-93).

In the process, the pharmaceutical maquillages acting as a color are charged, also transported to a chamber where in dissipation and disposition takes place.

Technology:

For medication of oral cure unit i.e. Accudep core is separated by erosional polymer flicks.

Illustrates It contains 6 layers each contains and each subcaste contains accudep core which in turn contained by a polymer core the layers are separated by rate controlling flicks and an impermeable coating is applied to the lozenge form.

The variables that affected medicine release include rate controlling film composition, quantum of medicine per subcaste, number of layers, immediate release rudiments, extend of content by on co passable coating. Rate controlling flicks was prepared with cellulosic material, polyethylene oxide film (94-100).

II. CONCLUSION

The oral route of administration is the most preferred route by patients for gastrointestinal drug delivery.

REFERENCES:

[1]. Acosta, E. (2009). Bioavailability of nanoparticles in nutrient and nutraceutical delivery. Curr. Opin. Colloid Interface Sci. 14, 3–15. doi: 10.1016/ j.cocis.2008.01.002

[2]. Ahmad, N., Alam, M. A., Ahmad, R., Umar, S., and Jalees Ahmad, F. (2018). Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. J. Microencapsul. 35 (4), 327–343. doi: 10.1080/02652048.2018.1485755

[3]. Albenberg, L. G., and Wu, G. D. (2014). Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146 (6), 1564–1572. doi: 10.1053/j.gastro.2014.01.058

[4]. Al-Gousous, J., Tsume, Y., Fu, M., Salem, I. I., and Langguth, P. (2017). Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems. Mol. Pharm. 14 (12), 4209–4219. doi: 10.1021/acs.molpharmaceut.6b00877

[5]. Ali, H., Weigmann, B., Neurath, M. F., Collnot, E. M., Windbergs, M., and Lehr, C.

[6]. M. (2014). Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J. Control Release 183, 167–177. doi: 10.1016/j.jconrel.2014.03.039

[7]. Allen, L. V., Popovich, N. G., and Ansel, H. C. (2011). Ansel"s pharmaceutical dosage forms and drug delivery systems. 9th ed. (Philadelphia: Lippincott Williams & Wilkins).

[8]. Anderson, K. E., Eliot, L. A., Stevenson, B. R., and Rogers, J. A. (2001). Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharmaceut. Res. 18 (3), 316–322. doi: 10.1023/A:1011002913601.

[9]. Antoni, L., Nuding, S., Wehkamp, J., and Stange, E. F. (2014). Intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 20 (5), 1165–1179. doi: 10.3748/wjg.v20.i5.1165

[10]. Atuma, C., Strugala, V., Allen, A., and Holm, L. (2001). The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest Liver Physiol. 280 (5), G922–G929. doi: 10.1152/ ajpgi.2001.280.5.G922

[11]. Awasthi, R., and Kulkarni, G. T. (2016). Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand? Drug Deliv. 23 (2), 378–394. doi: 10.3109/ 10717544.2014.936535

[12]. Banerjee, A., and Mitragotri, S. (2017). Intestinal patch systems for oral drug delivery. Curr. Opin. Pharmacol. 36, 58–65. doi: 10.1016/j.coph.2017.08.005

[13]. Banerjee, A., Lee, J., and Mitragotri, S. (2016a). Intestinal mucoadhesive devices for oral delivery of insulin. Bioengineering

Trans. Med. 1 (3), 338–346. doi: 10.1002/btm2.10015

[14]. Banerjee, A., Qi, J., Gogoi, R., Wong, J., and Mitragotri, S. (2016b). Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J. Control Release 238, 176–185. doi: 10.1016/j.jconrel.2016.07.051

[15]. Banerjee, A., Pathak, S., Subramanium, V. D., Dharanivasan, G., Murugesan, R., and Verma, R. S. (2017). Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discovery Today 22 (8), 1224–1232. doi: 10.1016/j.drudis.2017.05.006

[16]. Bannunah, A. M., Vllasaliu, D., Lord, J., and Stolnik, S. (2014). Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol. Pharm. 11 (12), 4363–4373. doi: 10.1021/mp500439c.

[17]. Adeoye O and Cabral-Marques H (2017) Cyclodextrin nanosystems in oral drug de-livery: a mini review. Int J Pharm 531:521–531.

[18]. Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem SS,

[19]. Oben K, Munagala R, Bondada S, et al. (2017) Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine 13:1627–1636.

[20]. Ainslie KM, Kraning CM, and Desai TA (2008) Microfabrication of an asymmetric,multi-layered microdevice for controlled release of orally delivered therapeutics. Lab Chip 8:1042–1047.

[21]. Alshehri SM, Al-Lohedan HA, Al-Farraj E, Alhokbany N, Chaudhary AA,and Ahamad T (2016) Macroporous natural capsules extracted from Phoenix dac-tylifera L. spore and their application in oral drugs delivery. Int J Pharm 504: 39–47.

[22]. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, and Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Bio-technol 29:341–345.

[23]. Amet N, Wang W, and Shen WC (2010) Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release 141: 177–182.

[24]. Aminabhavi TM, Nadagouda MN, Joshi SD, and More UA (2014) Guar gum as platform for the oral controlled release of therapeutics. Expert Opin Drug Deliv 11: 753–766.

[25]. Anderson KE, Eliot LA, Stevenson BR, and Rogers JA (2001) Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm Res 18:316–322.

[26]. Andrews GP, Laverty TP, and Jones DS (2009) Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 71:505–518.

[27]. Baek JS and Cho CW (2017) Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm 117:132–140.

[28]. Bai JPF (2016) Pharmacodynamics and systems pharmacology approaches to repurposing drugs in the wake of global health burden. J Pharm Sci 105: 3007–3012.

[29]. Balk A, Wiest J, Widmer T, Galli B, Holzgrabe U, and Meinel L (2015) Transformation of acidic poorly water soluble drugs into ionic liquids. Eur J Pharm Biopharm 94:73–82.

[30]. Banerjee A, Ibsen K, Brown T, Chen R, Agatemor C, and Mitragotri S (2018) Ionic liquids for oral insulin delivery. Proc Natl Acad Sci USA 115:7296–7301.

[31]. Banerjee A, Lee J, and Mitragotri S (2016) Intestinal mucoadhesive devices for oral delivery of insulin. Bioeng Transl Med 1:338–346.

[32]. Banerjee A and Mitragotri S (2017) Intestinal patch systems for oral drug delivery. Curr Opin Pharmacol 36:58–65.

[33]. Banerjee A, Wong J, Gogoi R, Brown T, and Mitragotri S (2017) Intestinal micro-patches for oral insulin delivery. J Drug Target 25:608–615.

[34]. Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL, Mazdiyasni H, Kogan L, et al. (2016) Oral, ultra-long-lasting drug delivery: ap-plication toward malaria elimination goals. Sci Transl Med 8:365ra157.

[35]. Bernkop-Schnürch A (2005) Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 57:1569–1582.

[36]. Betancourt T, Pardo J, Soo K, and Peppas NA (2010) Characterization of pH-responsive hydrogels of poly(itaconic acid-g-ethylene glycol) prepared by UV-initiated free radical polymerization as biomaterials for oral delivery of bio- active agents. **J** Biomed Mater Res A 93:175–188.

[37]. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson k.

[38]. Karlsson G, Pohlmann H, and Wigal S (2003) Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 5:833–841.

[39]. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, and Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 27:1821–1829.

[40]. Cárdenas-Bailón F, Osorio-Revilla G, and Gallardo-Velázquez T (2015) Microencapsulation of insulin using a W/O/W double emulsion followed by complex co- acervation to provide protection in the gastrointestinal tract. J Microencapsul 32: 308–316.

[41]. Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, et al. (2018) Drug repurposing from the perspective of pharmaceutical companies. Br **J** Pharmacol 175:168–180.

[42]. Chaturvedi K, Ganguly K, Nadagouda MN, and Aminabhavi TM (2013) Polymeric

[43]. hydrogels for oral insulin delivery. J Control Release 165:129–138.

[44]. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, and Saltzman WM (2015a) A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 14:239–247.

[45]. Cheng Q, Shi H, Huang H, Cao Z, Wang J, and Liu Y (2015b) Oral delivery of a

[46]. platinum anticancer drug using lipid assisted polymeric nanoparticles. Chem Commun (Camb) 51:17536–17539.

[47]. Chirra HD and Desai TA (2012) Emerging microtechnologies for the development of oral drug delivery devices. Adv Drug Deliv Rev 64:1569–1578.

[48]. Choonara BF, Choonara YE, Kumar P, Bijukumar D, du Toit LC, and Pillay V (2014)

[49]. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 32:1269–1282.

[50]. Cipolla DC and Gonda I (2012) Formulation technology to repurpose drugs for inhalation delivery. Drug Discov Today Ther Strat 8:123–130.

[51]. Cong Z, Shi Y, Wang Y, Wang Y, Niu J, Chen N, and Xue H (2018) A novel controlled drug delivery system based on alginate hydrogel/chitosan micelle composites. Int J Biol Macromol 107 (Pt A):855–864.

[52]. Czuba E, Diop M, Mura C, Schaschkow A, Langlois A, Bietiger W, Neidl R, Virciglio A, Auberval N, Julien-David D, et al. (2018) Oral insulin delivery, the challenge to increase insulin bioavailability: influence of surface charge in nanoparticle system. Int J Pharm 542:47–55.

[53]. Das S and Subuddhi U (2015) pH-Responsive guar gum hydrogels for controlled delivery of dexamethasone to the intestine. Int J Biol Macromol 79:856–863.

[54]. Del Curto MD, Maroni A, Palugan L, Zema L, Gazzaniga A, and Sangalli ME (2011) Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds. **J** Pharm Sci 100:3251–3259.

[55]. Delie F (1998) Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 34:221–233.

[56]. Donovan JD, Bauer L, Fahey GC Jr, and Lee Y (2017) In vitro digestion and fermentation of microencapsulated

tributyrin for the delivery of butyrate. J Food Sci 82:1491–1499.

[57]. Du H, Liu M, Yang X, and Zhai G (2015) The design of pH-sensitive chitosan-based formulations for gastrointestinal delivery. Drug Discov Today 20:1004–1011.

[58]. Du W, Fan Y, Zheng N, He B, Yuan L, Zhang H, Wang X, Wang J, Zhang X,and Zhang Q (2013) Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 34:794–806.

[59]. Eiamtrakarn S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata N, Murakami M,and Takada K (2002) Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. Biomaterials 23:145–152.

[60]. El-Aassar MR, Hafez EE, El-Deeb NM, and Fouda MM (2014) Microencapsulation of lectin anti-cancer agent and controlled release by alginate beads, biosafety ap- proach. Int J Biol Macromol 69:88–94.

[61]. Elder DP, Holm R, and Diego HL (2013) Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. Int J Pharm 453:88–100.

[62]. Fleming AB, Carlson DR, Varanasi RK, Grima M, Mayock SP, Saim S, and Kopecky EA (2016) Evaluation of an extended-release, abuse-deterrent, microsphere-in- capsule analgesic for the management of patients with Chronic Pain With Dys- phagia (CPD). Pain Pract 16:334–344.

[63]. Fonseca-Santos B and Chorilli M (2018) An overview of polymeric dosage forms in buccal drug delivery: state of art, design of formulations and their in vivo perfor- mance evaluation. Mater Sci Eng C 86:129–143.

[64]. Fowler R, Vllasaliu D, Trillo FF, Garnett M, Alexander C, Horsley H, Smith B, Whitcombe I, Eaton M, and Stolnik S (2013) Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small 9:3282–3294.

[65]. Fox CB, Chirra HD, and Desai TA (2014) Planar bioadhesive microdevices: a new technology for oral drug delivery. Curr Pharm Biotechnol 15:673–683.

[66]. Fox CB, Kim J, Le LV, Nemeth CL, Chirra HD, and Desai TA (2015) Micro/nanofabricated platforms for oral drug delivery. J Control Release 219:431–444.

[67]. Ganugula R, Arora M, Guada M, Saini P, and Kumar MNVR (2017a) Noncompetitive active transport exploiting intestinal transferrin receptors for oral delivery of proteins by tunable nanoplatform. ACS Macro Lett 6:161–164.

[68]. Ganugula R, Arora M, Saini P, Guada M, and Kumar MNVR (2017b) Next generation

[69]. precision-polyesters enabling optimization of ligand-receptor stoichiometry for modular drug delivery. **J** Am Chem Soc 139:7203–7216.

[70]. Gao X, Cao Y, Song X, Zhang Z, Zhuang X, He C, and Chen X (2014) Biodegradable,pH-responsive carboxymethyl cellulose/poly(acrylic acid) hydrogels for oral insulin delivery. Macromol Biosci 14:565–575.

[71]. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, and Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603.

[72]. Guada M, Lana H, Gil AG, Dios-Viéitez M del C, and Blanco-Prieto MJ (2016) Cyclosporine A lipid nanoparticles for oral administration: pharmacodynamics and safety evaluation. Eur **J** Pharm Biopharm 101:112–118.

[73]. Guarascio AJ and Slain D (2015) Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. Pharmacotherapy 35:208–219.

[74]. Gupta V, Hwang BH, Doshi N, Banerjee A, Anselmo AC, and Mitragotri S (2016) Delivery of exenatide and insulin using mucoadhesive intestinal devices. Ann Biomed Eng 44:1993–2007.

[75]. Gupta V, Hwang BH, Lee J, Anselmo AC, Doshi N, and Mitragotri S (2013) Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. **J** Control Release 172:753–762.

[76]. Hascicek C, Rossi A, Colombo P, Massimo G, Strusi OL, and Colombo

G (2011) Assemblage of drug release modules: effect of module shape and position in the assembled systems on floating behavior and release rate. Eur **J** Pharm Biopharm 77:116–121.

[77]. He H, Cao X, and Lee LJ (2004) Design of a novel hydrogel-based intelligent system for controlled drug release. J Control Release 95:391–402.

[78]. Hong Y, Liu G, and Gu Z (2016) Recent advances of starch-based excipients used in extended-release tablets: a review. Drug Deliv 23:12–20.

[79]. Horava SD, Moy KJ, and Peppas NA (2016) Biodegradable hydrophilic carriers for the oral delivery of hematological factor IX for hemophilia B treatment. Int J Pharm 514:220–228.

[80]. Hoyer H, Greindl M, and Bernkop-Schnürch A (2009) Design and in vivo evaluation of a patch system based on thiolated polymers. **J** Pharm Sci 98:620–627.

[81]. Huang L, Injac SG, Cui K, Braun F, Lin Q, Du Y, Zhang H, Kogiso M, Lindsay H, Zhao S, et al. (2018) Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Sci Transl Med 10: eaat0150.

[82]. Hussain N, Jani PU, and Florence AT (1997) Enhanced oral uptake of tomato lectin- conjugated nanoparticles in the rat. Pharm Res 14:613–618.

[83]. Imran M (2014) inventors. Swallowable drug delivery device and methods of drug delivery. U.S. Patent 8,721,620. Assignee: Rani Therapeutics LLC.

[84]. Izadi Z, Divsalar A, Saboury AA, and Sawyer L (2016) b-Lactoglobulin-pectin nanoparticle-based oral drug delivery system for potential treatment of colon cancer. Chem Biol Drug Des 88:209–216.

[85]. Jani P, Halbert GW, Langridge J, and Florence AT (1990) Nanoparticle uptake by therat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 42:821–826.

[86]. Kaithwas V, Dora CP, Kushwah V, and Jain S (2017) Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids Surf B Bio-interfaces 154:10–20.

[87]. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, and Kalluri R (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546:498–503.

[88]. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, et al. (2005) A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 102:12095–12100.

[89]. Katsuma M, Watanabe S, Takemura S, Sako K, Sawada T, Masuda Y, Nakamura K, Fukui M, Connor AL, and Wilding IR (2004) Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. **J** Pharm Sci 93: 1287–1299.

[90]. Kaur G, Arora M, Ganugula R, and Kumar MNVR (2019) Double-headed nanosystems for oral drug delivery. Chem Commun 55:4761–4764.

[91]. Khaled SA, Alexander MR, Wildman RD, Wallace MJ, Sharpe S, Yoo J, and Roberts CJ (2018) 3D extrusion printing of high drug loading immediate release para- cetamol tablets. Int J Pharm 538:223–230.

[92]. Khaled SA, Burley JC, Alexander MR, Yang J, and Roberts CJ (2015) 3D printing of tablets

[93]. containing multiple drugs with defined release profiles. Int J Pharm 494:643–650.

[94]. Kim S, Diab R, Joubert O, Canilho N, and Pasc A (2016) Core-shell microcapsules of

[95]. solid lipid nanoparticles and mesoporous silica for enhanced oral delivery of cur-cumin. Colloids Surf B Biointerfaces 140:161–168.

[96]. Kirsch K, Hanke U, and Weitschies W (2017) An overview of intestinal wafers for oral drug delivery. Eur J Pharm Biopharm 114:135–144.

[97]. Knipe JM, Chen F, and Peppas NA (2015) Enzymatic biodegradation of hydrogels for protein delivery targeted to the small intestine. Biomacromolecules 16:962–972. Koetting MC and Peppas NA (2014) pH-Responsive poly(itaconic acid-co-N-vinylpyrrolidone) hydrogels with reduced ionic strength loading solutions offer improved oral delivery potential for high isoelectric point-exhibiting therapeutic proteins. Int **J** Pharm 471:83–91.

[98]. Kumar P, Singh AK, Raj V, Rai A, Keshari AK, Kumar D, Maity B, Prakash A, Maiti S, and Saha S (2018) Poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid for improved treatment of hepatic cancer: characterization, in vitro and in vivo evaluations. Int J Nanomedicine 13:975–990.

[99]. Kyobula M, Adedeji A, Alexander MR, Saleh E, Wildman R, Ashcroft I, Gellert PR,and Roberts CJ (2017) 3D inkjet printing of tablets exploiting bespoke complex geometries for controlled and tuneable drug release. **J** Control Release 261: 207–215.

[100]. Lamb YN, Garnock-Jones KP, and Keam SJ (2016) Oxycodone DETERx$^{®}$ ER capsules: a review in severe, chronic pain. Drugs 76:1759–1769.

[101]. Lamprou DA, Venkatpurwar V, and Kumar MNVR (2013) Atomic force microscopy images label-free, drug encapsulated nanoparticles in vivo and detects difference in tissue mechanical properties of treated and untreated: a tip for nanotoxicology.PLoS One 8:e64490.

[102]. Langer R and Weissleder R (2015) Nanotechnology. JAMA 313:135–136.

[103]. Lee S, Kim YC, and Park JH (2016) Zein-alginate based oral drug delivery systems: protection and release of therapeutic proteins. Int J Pharm 515:300–306.

[104]. Leonard TW, Lynch J, McKenna MJ, and Brayden DJ (2006) Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 3:685–692.

[105]. Li L, Jiang G, Yu W, Liu D, Chen H, Liu Y, Huang Q, Tong Z, Yao J, and Kong X (2016) A composite hydrogel system containing glucose-responsive nanocarriers for oral delivery of insulin. Mater Sci Eng C 69:37–45.